Biohaven (BHVN) Competitors

Biohaven (NYSE:BHVN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment.

Is BHVN or SMMT more profitable?

Summit Therapeutics' return on equity of -85.42% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-225.12%	-158.89%
Summit Therapeutics	N/A	-85.42%	-52.66%

Does the media favor BHVN or SMMT?

In the previous week, Biohaven had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Biohaven and 4 mentions for Summit Therapeutics. Biohaven's average media sentiment score of 0.99 beat Summit Therapeutics' score of 0.44 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in BHVN or SMMT?

88.8% of Biohaven shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 16.0% of Biohaven shares are held by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer BHVN or SMMT?

Biohaven currently has a consensus price target of $63.15, indicating a potential upside of 64.57%. Summit Therapeutics has a consensus price target of $33.57, indicating a potential upside of 48.77%. Given Biohaven's stronger consensus rating and higher possible upside, research analysts plainly believe Biohaven is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Summit Therapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Does the MarketBeat Community favor BHVN or SMMT?

Biohaven received 99 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 67.22% of users gave Biohaven an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Biohaven	Outperform Votes 402 67.22%	Underperform Votes 196 32.78%
Summit Therapeutics	Outperform Votes 303 58.38%	Underperform Votes 216 41.62%

Which has more volatility & risk, BHVN or SMMT?

Biohaven has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.

Which has stronger earnings & valuation, BHVN or SMMT?

Biohaven has higher earnings, but lower revenue than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$408.17M	-$9.35	-4.10
Summit Therapeutics	$700K	23,773.28	-$614.93M	-$0.28	-80.59

Summary

Biohaven beats Summit Therapeutics on 12 of the 17 factors compared between the two stocks.